Travere Therapeutics Completes Enrollment in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy
02 juin 2021 08h00 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, June 02, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced completion of patient enrollment in the Phase 3 PROTECT Study. The pivotal PROTECT Study is...
Travere Therapeutics to Present at Upcoming Investor Conferences
27 mai 2021 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, May 27, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will present at the following upcoming virtual investor conferences in...
Travere Therapeutics Reports First Quarter 2021 Financial Results
06 mai 2021 16h01 HE
|
Travere Therapeutics, Inc.
Pivotal PROTECT Study of sparsentan in IgA nephropathy nears completion of patient enrollment; topline proteinuria data expected 3Q21 Net product sales of $47.4 million for the first quarter of...
Cytta Premiers Exciting new Website and Scintillating Cytta Show Double Feature
07 avr. 2021 08h00 HE
|
Cytta Corp.
Las Vegas , April 07, 2021 (GLOBE NEWSWIRE) -- --Cytta Corp (OTCPINK: CYCA) is pleased to announce the Company’s newly designed and updated website at https://cytta.com/ is up and running and...
Cytta’s IGAN System Helps First Responders Achieve Daily Record Setting Vaccination Totals
22 mars 2021 10h00 HE
|
Cytta Corp.
Las Vegas , March 22, 2021 (GLOBE NEWSWIRE) -- --Cytta Corp (OTCPINK: CYCA)To help deal with currently unprecedented Public Health crisis, Cytta provided our IGAN incident command technology to...
Texas Covid Vaccination Program Utilizing IGAN Screens on the YouTube Cytta Show
10 mars 2021 08h00 HE
|
Cytta Corp.
Las Vegas , March 10, 2021 (GLOBE NEWSWIRE) -- --Cytta Corp (OTCPINK: CYCA) We at Cytta are pleased and proud to be providing our IGAN incident command technology to assist in keeping Americans safe...
Initial Episode of the Cytta Show Screens on YouTube Today
03 mars 2021 08h00 HE
|
Cytta Corp.
Las Vegas , March 03, 2021 (GLOBE NEWSWIRE) -- --Cytta Corp (OTCPINK: CYCA) Cytta Corp. is pleased to announce that the inaugural version of the “Cytta Show” has now been posted on our YouTube...
Travere Therapeutics to Present at Upcoming Investor Conferences
22 févr. 2021 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will present at the following upcoming virtual investor conferences in...
Cytta CEO Announces Great Strides in SUPR and IGAN Product Development and Market Introductions
22 févr. 2021 08h00 HE
|
Cytta Corp.
Las Vegas , Feb. 22, 2021 (GLOBE NEWSWIRE) -- --Cytta Corp (OTCPINK: CYCA) Cytta’s CEO, Gary Campbell is pleased to share the following open letter to all shareholders. The letter provides an...
Travere Therapeutics Announces Pricing of Public Offering of Common Stock
11 févr. 2021 22h03 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of an underwritten public offering of 6,550,000 shares of its common stock at a...